SillaJen Launches Global Scientific Advisory Board... "Recruiting Top Experts in Cancer Treatment"

[Asia Economy Reporter Hyunseok Yoo] On the 20th, SillaJen announced the launch of a Scientific Advisory Board (SAB) group directly under the CEO to strengthen new drug development research capabilities and clinical expertise.

The SAB group has recruited Dr. Steve Morris from St. Jude Children's Research Hospital and Dr. Howard Kaufman from Harvard Medical School, both recognized as leading authorities in the field of oncology.

Dr. Steve Morris is regarded as a master in oncology, having researched tumors for 25 years at St. Jude Children's Research Hospital in the United States. In particular, he elucidated the ALK (Anaplastic Lymphoma Kinase) mechanism in non-small cell lung cancer, leading to the market introduction of ALK inhibitors such as Xalkori (Pfizer), Zykadia (Novartis), Alecensa (Roche), and Alunbrig (Takeda).

He also discovered various oncogenes that cause cancers, including BCL10 (B-cell lymphoma/leukemia gene 10) and NPM-MLF1 (Nucleophosmin-myeloid leukemia factor 1), and has introduced over 150 achievements through leading international journals.

Dr. Howard Kaufman, a top authority in the field of oncolytic viruses and melanoma, has also joined the SAB. Dr. Kaufman led the pivotal study for Imlygic (Amgen), the world's first commercially successful oncolytic virus, and is conducting research and clinical trials on melanoma treatments at the Harvard Cancer Center.

The SillaJen SAB group will provide advisory services throughout all processes, including clinical trials of SillaJen's Pexa-Vec, the introduction and validation of newly planned candidate substances, and clinical development.

In particular, they will be involved in the validation process of new pipelines to be introduced through M2N-GFB (Greenfire Bio), as well as clinical trials of the pipeline candidates Pexa-Vec and SJ-600.

A SillaJen official stated, “The recruitment of global top authorities in oncology will be an opportunity to further strengthen the capabilities of our oncology research and development company,” adding, “We will do our best to create new momentum for SillaJen’s leap forward through the SAB group’s abundant knowledge and experience.”